Jubilant Therapeutics Inc.

3 clinical trials · Sponsor

Record	Firm	Date
Phase 1/2 Study Evaluating the Safety, PK/PD, and Clinical Activity of Oral JBI-778 in Patients With Brain Metastases, Leptomeningeal Disease, or Recurrent High Grade Glioma (NCT07751744)	Jubilant Therapeutics Inc.	2028-04-01
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis (NCT07612280)	Jubilant Therapeutics Inc.	2024-10-21

Every clearance here is in the API, with alerts when new ones post.